Michael Untch
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
Papers in
- Cancer Research 357
- Breast Cancer Treatment Studies 349
- Oncology 179
- HER2/EGFR in Cancer Research 110
- Cancer Treatment and Pharmacology 23
- Co-authors
- Gϋnter von Minckwitz (73 shared papers)Sibylle Loibl (120 shared papers)Gottfried E. Konecny (27 shared papers)Christian Jackisch (79 shared papers)Jens Huober (64 shared papers)Peter Andreas Fasching (81 shared papers)Valentina Nekljudova (49 shared papers)Ingo Bauerfeind (42 shared papers)
- Journals
- Annals of Oncology (76 papers)Breast Care (54 papers)Journal of Clinical Oncology (36 papers)European Journal of Cancer (36 papers)Breast Cancer Research and Treatment (22 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Michael Untch
597 papers receiving 54.5k citations
Michael Untch's Hit Papers
Peers
Comparison fields: 5 of 153
- Cancer Research 26.6k
- Oncology 17.9k
- Radiology, Nuclear Medicine and Imaging 3.3k
- Pulmonary and Respiratory Medicine 4k
- Pathology and Forensic Medicine 2.1k
Countries citing papers authored by Michael Untch
This map shows the geographic impact of Michael Untch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Untch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Untch more than expected).
Fields of papers citing papers by Michael Untch
This network shows the impact of papers produced by Michael Untch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Untch. The network helps show where Michael Untch may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Untch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 631 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Hit paper breakdown → | 2005 | 4124 |
| 2 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Hit paper breakdown → | 2014 | 3695 |
| 3 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Hit paper breakdown → | 2013 | 2987 |
| 4 | Pembrolizumab for Early Triple-Negative Breast Cancer Hit paper breakdown → | 2020 | 2318 |
| 5 | Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes Hit paper breakdown → | 2012 | 2112 |
| 6 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Hit paper breakdown → | 2018 | 2015 |
| 7 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Hit paper breakdown → | 2017 | 1689 |
| 8 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Hit paper breakdown → | 2007 | 1246 |
| 9 | Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study Hit paper breakdown → | 2013 | 1125 |
| 10 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2012 | 1099 |
| 11 | Association analysis identifies 65 new breast cancer risk loci Hit paper breakdown → | 2017 | 1040 |
| 12 | Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers Hit paper breakdown → | 2014 | 868 |
| 13 | Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Hit paper breakdown → | 2014 | 810 |
| 14 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Hit paper breakdown → | 2017 | 806 |
| 15 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Hit paper breakdown → | 2018 | 775 |
| 16 | Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells Hit paper breakdown → | 2006 | 772 |
| 17 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Hit paper breakdown → | 2018 | 620 |
| 18 | 2006 | 598 | |
| 19 | A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study Hit paper breakdown → | 2019 | 569 |
| 20 | 2011 | 522 |
About Michael Untch
Michael Untch is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 631 papers that have together received 56.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (349 papers), HER2/EGFR in Cancer Research (110 papers), Advanced Breast Cancer Therapies (45 papers), BRCA gene mutations in cancer (33 papers), Breast Lesions and Carcinomas (28 papers), Cancer Treatment and Pharmacology (23 papers), Erythropoietin and Anemia Treatment (10 papers) and Ovarian cancer diagnosis and treatment (10 papers). The work is most often cited by research in Cancer Research (26.6k citations), Oncology (17.9k citations), Radiology, Nuclear Medicine and Imaging (3.3k citations), Pulmonary and Respiratory Medicine (4k citations) and Pathology and Forensic Medicine (2.1k citations). Michael Untch has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Gϋnter von Minckwitz, Sibylle Loibl, Gottfried E. Konecny, Christian Jackisch, Jens Huober, Peter Andreas Fasching, Valentina Nekljudova, Ingo Bauerfeind, Jens‐Uwe Blohmer and Wolfgang EIERMANN. Their work appears in journals such as Annals of Oncology, Breast Care, Journal of Clinical Oncology, European Journal of Cancer and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.